Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Retained Earnings (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Retained Earnings for 15 consecutive years, with -$166.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 8.23% year-over-year to -$166.7 million, compared with a TTM value of -$166.7 million through Sep 2025, down 8.23%, and an annual FY2024 reading of -$155.7 million, down 6.12% over the prior year.
  • Retained Earnings was -$166.7 million for Q3 2025 at BioRestorative Therapies, down from -$163.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$105.5 million in Q1 2021 and bottomed at -$166.7 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$141.0 million, with a median of -$144.4 million recorded in 2023.
  • The sharpest move saw Retained Earnings crashed 49.31% in 2021, then decreased 1.59% in 2022.
  • Year by year, Retained Earnings stood at -$134.1 million in 2021, then fell by 1.59% to -$136.3 million in 2022, then decreased by 7.64% to -$146.7 million in 2023, then fell by 6.12% to -$155.7 million in 2024, then dropped by 7.09% to -$166.7 million in 2025.
  • Business Quant data shows Retained Earnings for BRTX at -$166.7 million in Q3 2025, -$163.7 million in Q2 2025, and -$161.0 million in Q1 2025.